Cell and Gene Therapy Contract Development and Manufacturing Organization Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type, Product Type, End User, and Geography

Description

List of Tables

According to our new research study on "Cell and Gene Therapy Contract Development and Manufacturing Organization Market Forecast to 2031 -Global Analysis - by Service Type, Product Type, End User, and Geography," the market is anticipated to grow from US$ 6.22 billion in 2024 and is projected to reach US$ 31.86 billion by 2031; it is expected to register a CAGR of 26.4% during 2025-2031. Increasing clinical trials for innovative therapies and surging regulatory approvals and commercialization are contributing to the growing cell and gene therapy contract development and manufacturing organization market size. However, the high manufacturing complexities hampers the cell and gene therapy contract development and manufacturing organization market growth. Further, rising integration of AI and digital transformation is expected to bring in new cell and gene therapy contract development and manufacturing organization market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for cell and gene therapy contract development and manufacturing organization in the world. The US is observing growing advancements in biotechnology, an increasing prevalence of genetic diseases, and surging demand for specialized manufacturing services. As per the estimates of the US Government Accountability Office published in October 2021, ~25 to 30 million people suffer from rare diseases in the country. As per the Food and Drug Administration (FDA), more than 7,000 rare diseases affect over 30 million people in the country. The growing understanding of these diseases has led to a surge in gene therapy development. CDMOs play a crucial role in this space by providing specialized services for the development and manufacturing of gene therapies targeting rare genetic disorders.

In 2023, the US FDA approved numerous cell and gene therapies, including gene-editing treatments targeting rare diseases. Therapies such as exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel for sickle cell disease, as well as valoctocogene roxaparvovec for severe hemophilia A, have received FDA approval, highlighting the potential of gene therapies in addressing rare disease challenges. The accelerated regulatory pathways, such as the Regenerative Medicine Advanced Therapy (RMAT) designation, have spurred biotechnology companies to partner with CDMOs for scaling production.

Investments in manufacturing infrastructure have bolstered the market growth. The National Cell Manufacturing Consortium, established through collaboration between 15 academic institutes, over 25 companies, and government agencies, aims to enable cost-effective, large-scale manufacturing of cell therapies. In addition, strategic collaborations between CDMOs, academic institutions, and biopharma companies also contribute to market growth.

Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis

Access to Specialized Facilities and Technologies to Provide Market Opportunities in Future

The demand for cell and gene therapies is driving biopharmaceutical companies toward CDMOs that can provide cutting-edge facilities and technologies, which are required to scale up production while ensuring quality, compliance, and regulatory approval. These specialized capabilities are essential for the production of complex and personalized therapies, which require advanced infrastructure to maintain high manufacturing standards. Cell and gene therapies, including gene editing, viral vector production, and personalized medicine, require specialized facilities equipped with the latest technologies. The production of viral vectors used in gene therapies requires GMP standard facilities to ensure the safety, consistency, and quality of the final product. These facilities should be equipped to handle complex biological materials, such as live cells and genetically modified organisms, in controlled and monitored environments. The increasing adoption of automated cell culture systems, continuous manufacturing, and digital quality monitoring systems enhances the growth and efficiency of gene therapy production. For instance, in March 2025, Bharat Biotech invested US$ 75 million in its first cell and gene therapy facility in the southern India which is expected to launch new therapies in next 3 years for oncology and rare disease.

The need for specialized facilities creates a substantial opportunity for CDMOs. It is cost-effective and efficient for biopharma companies to collaborate with CDMOs that have the required technology and facilities. For instance, in 2023, Bristol-Myers Squibb collaborated with a CDMO for the production of its CAR-T cell therapy, Breyanzi. This therapy involves harvesting, modifying, and expanding a patient's T-cells, a process requiring specialized technology and facilities to ensure the desired therapeutic effect. By leveraging CDMO expertise in specialized facilities, Bristol-Myers Squibb was able to scale production while ensuring regulatory compliance and quality. Thus, the soaring need for advanced manufacturing capabilities with advanced technology is expected to create future growth opportunities for the cell and gene therapy contract research and development organization market.

Cell and Gene Therapy Contract Development and Manufacturing Organization Market Report Segmentation Analysis

Key segments that contributed to the derivation of the cell and gene therapy contract development and manufacturing organization market analysis are service type, product type, and end user.

Based on service type, the cell and gene therapy contract development and manufacturing organization market is segmented into drug development and manufacturing, testing and regulatory services, and others. The drug development and manufacturing segment held the largest share of the market in 2024.

In terms of product type, the cell and gene therapy contract development and manufacturing organization market is bifurcated into gene therapy and cell therapy. The cell therapy segment dominated the market in 2024.

By end user, the cell and gene therapy contract development and manufacturing organization market is categorized into pharmaceutical companies, biopharmaceutical companies, and others. The biopharmaceutical companies segment dominated the market in 2024.

Cell and Gene Therapy Contract Development and Manufacturing Organization Market: Competitive Landscape and Key Developments

WuXi Biologics Inc, Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, Thermo Fisher Scientific Inc., AGC Biologics AS, Takara Bio Inc, FUJIFILM Holdings Corp, Pluri Inc, SK pharmteco Inc, Aenova Holding GmbH, and Minaris Advanced Therapies are among the key companies operating in the cell and gene therapy contract development and manufacturing organization market.

Statistics Canada, World Population Prospectus, Globocan, Brazilian Health Regulatory Agency (ANVISA), Alliance for Regenerative Medicine (ARM), and the Food and Drug Administration (FDA) are among the primary and secondary sources referred to while preparing the cell and gene therapy contract development and manufacturing organization market report.

Product Code: TIPRE00040769

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Landscape

4.1 Overview
4.2 Global Plasmid Manufacturing Market

5. Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics

5.1 Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increasing Clinical Trials for Innovative Therapies
- 5.2.2 Surging Regulatory Approvals and Commercialization
5.3 Market Restraints
- 5.3.1 High Manufacturing Complexities
5.4 Market Opportunities
- 5.4.1 Access to Specialized Facilities and Technologies
5.5 Future Trends
- 5.5.1 Rising Integration of AI and Digital Transformation
5.6 Impact of Drivers and Restraints:

6. Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Global Market Analysis

6.1 Cell And Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2021-2031
6.2 Cell And Gene Therapy Contract Development and Manufacturing Organization Market Forecast Analysis

7. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Analysis - by Service Type

7.1 Drug Development and Manufacturing
- 7.1.1 Overview
- 7.1.2 Drug Development and Manufacturing: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Testing and Regulatory Services
- 7.2.1 Overview
- 7.2.2 Testing and Regulatory Services: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)

8. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Analysis - by Product Type

8.1 Gene Therapy
- 8.1.1 Overview
- 8.1.2 Gene Therapy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Cell Therapy
- 8.2.1 Overview
- 8.2.2 Cell Therapy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)

9. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Analysis - by End User

9.1 Pharmaceutical Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical Companies: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Biopharmaceutical Companies
- 9.2.1 Overview
- 9.2.2 Biopharmaceutical Companies: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)

10. Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.2.2 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.2.2.1 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.2.2.2 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.2.2.3 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.2.3 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.2 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.2.3.2.1 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.2.3.2.2 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.2.3.2.3 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.2.3.3 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.2.3.3.1 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.2.3.3.2 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.2.3.3.3 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.2.3.4 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.2.3.4.1 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.2.3.4.2 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.2.3.4.3 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.3 Europe
- 10.3.1 Europe Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.3.2 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.3.2.1 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.3.2.2 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.3.2.3 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.3.3 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.2 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.2.1 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.2.2 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.2.3 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.3 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.3.1 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.3.2 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.3.3 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.4 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.4.1 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.4.2 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.4.3 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.5 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.5.1 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.5.2 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.5.3 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.6 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.6.1 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.6.2 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.6.3 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.7 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.7.1 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.7.2 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.7.3 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.4 Asia Pacific
- 10.4.1 Asia Pacific Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.4.2 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.4.2.1 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.4.2.2 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.4.2.3 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.4.3 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.2 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.2.1 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.2.2 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.2.3 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.3 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.3.1 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.3.2 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.3.3 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.4 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.4.1 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.4.2 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.4.3 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.5 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.5.1 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.5.2 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.5.3 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.6 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.6.1 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.6.2 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.6.3 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.7 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.7.1 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.7.2 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.7.3 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.5.2 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.5.2.1 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.5.2.2 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.5.2.3 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.5.3 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.2 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.2.1 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.2.2 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.2.3 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.5.3.3 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.3.1 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.3.2 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.3.3 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.5.3.4 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.4.1 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.4.2 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.4.3 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.5.3.5 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.5.1 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.5.2 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.5.3 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.6 South and Central America
- 10.6.1 South and Central America Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.6.2 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.6.2.1 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.6.2.2 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.6.2.3 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
  - 10.6.2.4 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.6.2.5 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.6.2.5.1 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.6.2.5.2 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.6.2.5.3 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.6.2.6 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.6.2.6.1 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.6.2.6.2 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.6.2.6.3 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.6.2.7 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.6.2.7.1 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.6.2.7.2 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.6.2.7.3 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User

11. Competitive Landscape

11.1 Global Company Market Share Analysis, 2024

12. Industry Landscape

12.1 Overview
12.2 Expansion
12.3 New Product Development
12.4 Merger and Acquisition
12.5 Partnerships
12.6 Other Business Strategies

13. Company Profiles

13.1 WuXi Biologics Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Charles River Laboratories International Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Catalent Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Lonza Group AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AGC Biologics AS
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Takara Bio Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 FUJIFILM Holdings Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pluri Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 SK pharmteco Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Aenova Holding GmbH
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 Minaris Advanced Therapies
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
- 13.12.6 Key Developments

14. Appendix

14.1 Glossary of Terms
14.2 About The Insight Partners